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ABSTRACT 
 
Ceftaroline is a new fifth generation cephalosporin, 
active mostly against Gram-positive cocci, e.g. 
Staphylococcus aureus (including methicillin-
resistant Staphylococcus aureus). It is used in 
treating acute bacterial skin and skin structure 
infections, community acquired respiratory tract 
infections and methicillin-resistant S. aureus 
bacteremia. The main resistance mechanisms                 
of bacteria to β-lactam antibiotics, including 
ceftaroline, are mutations in PBP2a, PBP3 and 
PBP4. Clinically significant resistance has been 
noted among both archived and newly-isolated 
strains in a laboratory test using serial passages. 
Ceftaroline-resistant strains have also been found in 
patients suffering from cystic fibrosis, ventilator-
associated pneumonia and infectious endocarditis. 
Irresponsible antibiotic treatment using ceftaroline 
or other antibiotics (due to a possibility of a cross-
resistance) can lead to the spread of ceftaroline 
resistance and, consequently, its loss of value.  
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1. INTRODUCTION 
 
 Ceftaroline, a fifth generation cephalosporin, 
has been approved by the FDA (Food and Drug 
Administration) as a therapeutic option for both 
adult (in 2010) and pediatric (in 2016) patients 
suffering from acute bacterial skin and skin structure 
infections (ABSSSI) (including infections caused by 
MRSA), as well as community-acquired respiratory 
tract infections (CARTI), including community 
acquired bacterial pneumonia (CABP).The antibiotic 
has also been approved for treating patients with 
methicillin-resistant S. aureus bacteremia (MRSAB) 
and endocarditis. Despite being a new drug, on 
which many people has pinned their hopes, there  
are more and more reports of bacterial strains 
resistant to it. 
 
THE USE OF CEFTAROLINE  
 
 Ceftaroline is a broad-spectrum antibiotic [1], 
active against methicillin-susceptible and methi-
cillin-resistant Staphylococcus aureus (MSSA               
and MRSA), daptomycin-nonsusceptible (DNS)             
S. aureus, vancomycin-intermediate (VISA and 
hetero-VISA) and vancomycin-resistant (VRSA)             
S. aureus, methicillin-susceptible and methicillin-
resistant coagulase-negative streptococci (MSCoNS 
and MRCoNS), multidrug resistant Streptococcus 
pneumoniae, as well as many genera of Entero-
bacteriaceae (Escherichia coli, Klebsiella pneumo-
niae and K. oxytoca, Enterobacter aerogenes and           
E. cloacae, Citrobacter koseri and C. freundii, 
Proteus mirabilis, Serratia spp., Moraxella 
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catarrhalis, Haemophilus influenzae, Morganella 
morganii) [2-4]. Ceftaroline is ineffective against 
Pseudomonas spp., Enterococcus spp., Bacteroides 
fragilis and atypical bacteria (Mycoplasma pneu-
moniae, Chlamydia pneumoniae and Legionella 
pneumophila) [2].  
 In the USA, ceftaroline was put into use in 
October 2010 and in Europe - two years later. At 
first, it was used in treating ABSSSI and CARTI [5]. 
In vitro studies conducted by Gaikwead et al. show 
high effectiveness of the drug - among 30 MRSA 
strains sampled from different clinical materials, 2 
(6,67%) were resistant to it [6]. Moreover, clinical 
trials showed that it is well-tolerated by patients [2, 
5, 7] (most common side effects were: diarrhea, 
nausea, headache, pruritus [5]), leaving other 
antibiotics, with potentially severe side effects, such 
as nephrotoxicity, ototoxicity [8, 9] (vancomycin) or 
thrombocytopenia [9] (linezolid), as drugs of last 
resort [5]. A decreased percentage of patients having 
to stop therapy due to the side effects was noted - 
2,7% compared to 3,7% when treating with 
ceftriaxone or vancomycin with aztreonam [2]. 
Another in vitro study showed that when it comes to 
eradication of MRSA, ceftaroline is as effective as 
vancomycin, daptomycin and linezolid (when 
minimal inhibitory concentration for ceftaroline, 
MIC, ≤ 2 mg/l). It doesn’t matter then, whether the 
strain has developed mechanisms of resistance to 
linezolid or vancomycin [10].  
 Among adults with CABP, ceftaroline 
treatment was more effective than a ceftriaxone           
one [7, 11, 12]. Moreover, the difference between 
therapeutic effect of both drugs was less significant 
if in 96 hours prior to their usage no other 
antimicrobial drug had been used [11]. 
 Ceftaroline is the first intravenous antibiotic 
used among children over two months old to be 
approved by the FDA in over a decade [13]. 
Between 2012-2014 Pfaller et al. analyzed 3141 
samples (1681 associated with ABSSSI, 1460           
with CARTI) coming from pediatric patients from 
29 different centers. The strains of S. aureus,                    
S. pneumoniae, H. influenzae, P. aeruginosa, beta-
hemolytic streptococci, Enterobacteriaceae (inclu-
ding E. coli and Klebsiella spp.) and others were 
isolated. 99-100% of the Gram-positive bacteria,          
as well as H. influenzae strains, were ceftaroline-
susceptible. Also, the antibiotic was active against 
MRSA strains associated with ABSSSI and 
ceftriaxone-resistant S pneumoniae associated with 
CARTI [14]. The percentage of cured complicated 
ABSSSI and CABP in population of patients aged            
2 months to 17 years old was high [7]. 
 There’s also a known case of a ten year               
old girl who had had an accident and developed           
a MRSA sepsis (the bacteria were previously 
isolated from many of her wounds), which was 
fought off with relatively low dose of ceftaroline             
(2 x 9 mg/kg/d) - even though MIC of 1,5-4 mg/l 
suggested decreased susceptibility to it [15]. 
 A therapeutic success in treating MRSAB  
was also stated among adults in a study conducted 
by Zasowski et al. [16]. White et al. proved that 
ceftaroline is effective at treating patients with 
MRSAB who haven’t responded to other drugs [17]. 
There are also reports stating that ceftaroline 
combined with daptomycin can be effective in 
treating daptomycin-resistant or vancomycin-
intermediate resistant MRSA infectious endocarditis 
(IE) [18-20]. 
 
RESISTANCE MECHANISMS 
 
 Microorganisms for which the MIC value for 
ceftaroline is equal or less than 1 mg/l (1 μg/ml) are 
considered susceptible to this antibiotic. When the 
MIC ranges from 1 to 8 mg/l the microorganism is 
considered nonsusceptible and when the MIC 
exceeds 32 mg/l, the microorganism is resistant to 
ceftaroline [21-24].  
 Mechanisms of microbial resistance to 
ceftaroline are based on mutations within the 
penicillin binding protein (PBP) group, and are 
primarily observed in S. aureus [20-31]. Among the 
mutations present in PBP proteins, mutations were 
observed predominantly within the PBP2a protein 
[25] both inside the penicillin-binding domain 
(PBD) and outside the penicillin-binding domain 
(nPBD) [21, 29]. Mutations in PBD seem to 
correlate more frequently with nonsusceptibility, 
and mutations in nPBD with resistance to cefta-
roline. PBP3 and PBP4 were other mutated PBP to 
be proved to correlate with ceftaroline resistance. 
This type of resistance has been overcome by the 
combination of ceftaroline with very low methicillin 
or meropenem doses [24, 26]. 
 The PBP2a is a mutated variant of the PBP2 
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responsible for bacterial cell wall biosynthesis, 
providing microbial resistance to β-lactam antibio-
tics. Changes in the staphylococcal mecA gene result 
in conformational changes of the finished PBP2, 
which reduces its affinity to all β-lactam antibiotics 
[27]. It can be suspected that further mutations 
induced by environmental factors (ceftaroline 
therapy) within or outside the SCCmecA gene 
(Staphylococcal Cassette Chromosome mec) may 
result in resistance to fifth generation of cephalo-
sporins [25, 28], which seemed to be completely 
effective in the treatment of MRSA infections so far. 
However, studies conducted by Kelley WL et al. 
show that during the introduction of ceftaroline to 
use, variants of the PBP2a providing ceftaroline 
resistance to hospital-acquired MRSA (HA-MRSA) 
have already existed (Table 1) [29]. 
 Other factors leading to the increase of total 
resistance level in bacteria, include genes taking  
part in cell wall precursor formation and turnover, 
such as femA and femB genes, encoding proteins  
that take part in forming correct peptidoglycan 
pentaglycine interpeptide bridge, as well as fmhA, 
fmhB and fmhC genes, which encode proteins 
participating in forming peptidoglycan pentaglycine 
interpeptide. It was also noted that genes engaged             
in glutamine’s and glucosamine’s metabolism, such 
as femC and femD, can also cause the increase of 
bacterial resistance [32, 33]. 
 Greninger A et al. suggested that mutations 
within genes such as clpX endopeptidase, pp2c 
protein phosphatase and transcription terminator  
rho can influence resistance to ceftaroline of MRSA 
in mechanisms different than the one involving 
mecA [34]. 
 Chan LC et al. noted the significance of   
gdpP mutation, often identified within MRSA 
strains resistant to both ceftaroline and ceftobiprole. 
However, it’s role is yet to be discovered [26, 31]. 
  
 
 
Table 1. HA-MRSA strains isolated from University Hospital of Geneva’s patients’ blood between 1998-2003, showing 
primary resistance to ceftaroline (MIC > 1mg/l) [29]. 
Strain 
(GenBank no.) Molecular type SCCmec Mutations Year 
MIC (broth) 
(mg/l) 
12 ST228 I E239K 1998 2 
14 ST228 I E239K 1998 2 
13 ST247 I N146K, E150K, G246E 1998 4 
16 ST247 I N146K, E150K, G246E 1998 4 
56 ST228 I N146K 1999 2 
17 ST228 I N146K 1999 2 
21 ST228 I N146K 1999 2 
57 ST228 I N146K 2000 2 
25 ST228 I N146K 2000 2 
28 ST228 I N146K 2000 2 
30 ST228 I N146K 2000 4 
42 ST228 I N146K 2002 2 
48 ST228 I N146K 2003 2 
52 ST228 I N146K 2003 2 
 
 
 Chan LC et al. used the method of serial 
passages and the method of plasmid transduction to 
estimate the possibility of emergence of ceftaroline 
resistance and the potential consequences of its 
transmission in two strains of ceftaroline-passaged 
mutants: SF8300 and COL. In this way, mutants 
with MIC greater than 32 mg/l were obtained [26]. 
Lahiri SD et al. proved, using the method of serial 
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passages, that induction of ceftaroline-resistance 
(MIC ranging from 2 to 64 mg/l) is possible among 
strains ATCC 29213 (MIC: 0.25-4 mg/l), USA300 
(MIC: 1-8 mg/l) and ARC3824 (MIC: 8-64 mg/l). 
 Clinical strains of MRSA, investigated by 
Lahiri SD et al., have also shown the ability to          
rapid resistance development (manifesting itself as 
significant increase of MIC), as presented in Table 2 
[30]. It is a discovery of great importance, since 
passing bacteria imitates the situation in human 
organism when, due to incorrect dosage, too long 
therapy or insufficient penetration of the antibiotic 
to the tissue, in vivo MIC has not been achieved.  
Besides the mutation within PBP2A, strains with 
point mutation within PBP4, providing them cefta-
roline-resistance, were observed (strains TRN5426 
and TRN5549) [25]. 
 
 
 
Table 2. Clinical MRSA strains with significantly increased (compared to parental strains) MIC due to serial passages. 
Descendant strains are marked by adding (after the dash) following letters of the alphabet to the name of a parental               
strain [30]. 
Strain Molecular 
type 
SCC
mec 
Mutations 
of parental 
strain 
Additional 
mutations 
after passage 
Year Country 
MIC 
(broth) of 
parental 
strain 
(mg/l) 
MIC 
(broth) 
after 
passage 
(mg/l) 
ARC3824 ST228 I E239K, 
E447K  2010 Spain 8  
ARC3824-A ST228 I E239K, 
E447K Y446N 2010 Spain 8 64 
ARC3824-B ST228 I E239K, 
E447K A601S 2010 Spain 8 16 
ARC3824-C ST228 I E239K, 
E447K A601S 2010 Spain 8 16 
ARC3827 ST228 I E239K  2010 Thailand 2  
ARC3827-A ST228 I E239K - 2010 Thailand 2 4 
ARC3827-B ST228 I E239K - 2010 Thailand 2 4 
TRN5426 ST22 IV WT  2012 Portugal 2  
TRN5426-A ST22 IV WT - 2012 Portugal 2 8 
TRN5467 ST5 II 
N146K, 
L357I, 
I563T 
 2012 South 
Korea 
4  
TRN5467-A ST5 II 
N146K, 
L357I, 
I563T 
Y446N 2012 South 
Korea 
4 32 
TRN5467-B ST5 II 
N146K, 
L357I, 
I563T 
Y446N 2012 South 
Korea 
4 32 
TRN5549 ST22 IV E150K  2012 Portugal 2  
TRN5549-A ST22 IV E150K - 2012 Portugal 2 8 
 
 
 Moreover, there are more and more reports 
from all over the world, describing isolating from 
different clinical samples another MRSA strains 
capable of developing mechanisms of resistance to 
ceftaroline (Table 3). 
 Laboratory results are also confirmed by 
reported clinical cases. This problem is seen (among 
others) in patients with cystic fibrosis (CF), 
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probably due to the multitude of therapeutic cycles 
using the same antibiotic - in this case - ceftaroline. 
Such cases, as presented in Table 4, prove that 
increasing resistance to antibiotics observed in 
microbiological laboratories while passing bacteria, 
is also reflected in clinical environment. In these 
patients, resistance to ceftaroline and its limited 
clinical effectiveness were observed [22, 31]. The 
case of ceftaroline resistance was also reported             
for a strain isolated from the blood of a patient 
suffering from IE, as well as from the broncho-
alveolar lavage fluid (BALF) of a patient suffering 
from ventilation associated pneumonia (VAP)            
[35]. Molecular studies conducted on isolated 
MRSA strains revealed mutations in PBP2a [22,            
30, 31]. 
 
 
Table 3. MRSA strains with potential of clinical resistance to ceftaroline [25, 30]. 
Strain Molecular 
type SCCmec Mutations Country 
MIC 
(broth) 
(mg/l) 
TRN5420 ST239 III E239K Hungary 2 
TRN5427 ST36 II WT Greece 2 
TRN5428 ST239 III N146K, E150K, N204K, G246E Greece 4 
TRN5433 ST5 II K290Q Japan 4 
TRN5444 ST5 II K281R China 2 
TRN5454 ST5 II WT Japan 2 
TRN5458 ST239 III N146K Philippines 2 
TRN5471 ST228 I N146K, I563T Italy 4 
TRN5474 ST5 II N236K Taiwan 2 
TRN5475 ST239 III E239K China 2 
TRN0478 ST228 I N146K Hungary 2 
TRN5507 ST239 III N146K Russia 4 
TRN5521 ST228 I E239K, E447K Thailand 8 
TRN5536 ST239 III WT Turkey 2 
TRN5539 ST5 II E170K, N236K Taiwan 2 
TRN5552 ST239 III N146K, N204K, G246E South Africa 2 
TRN5562 ST22 IV E239K, G246E France 2 
TRN5563 ST239 with 
tpi-107 III N204K, T235I France 2 
TRN5572 ST5 II WT Italy 2 
ARC3824 ST228 I E239K, E447K Spain 8 
ARC3828 ST228 I E239K, E447K Thailand 8 
ARC3830 ST228 I E239K, E447K Thailand 8 
TRN5474 ST228 I N236K Taiwan 2 
TRN5472 ST228 I WT Italy 2 
TRN5545 ST239 III N146K Turkey 2 
TRN5418 ST5 I M122I, E150K Chile 2 
TRN5350 ST8 II N236K USA 2 
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Table 4. Summary of clinical cases [22, 30, 31]. 
Strain Disease Sample Mutation MIC (mg/l) 
THMS-4519 Cystic fibrosis Sputum Y446N 1,5 
THMS-3125 Cystic fibrosis Sputum Y446N, E447K >32 
THMS-5007 Cystic fibrosis Sputum E239K, Y446N, E447K >32 
THMS-5006 Cystic fibrosis Blood E239K, Y446N, E447K >32 
USA100 Infectious endocarditis Blood E447K 4 
USA100 Ventilation associated pneumonia BALF E447K 6 
 
 
 Pfaller MA et al. observed ceftaroline resi-
stance in one multi-drug resistant S pneumoniae 
strain. Molecular analysis revealed 31 altered 
aminoacids within the MurM relative to the standard 
R6 strain. Changes in PBPs, mainly PBP2x, were 
also detected [36]. 
 
EPIDEMIOLOGY  
 
 Despite being put into use only a few years 
ago, ceftaroline-resistant strains are detected in more 
and more countries. Moreover, it was proved that 
resistant strains have been existing for at least over  
a dozen years prior to introducing ceftaroline. In 
2015 Kelley et al. published the results of a study 
concerning 60 archival MRSA strains (collected 
between 1994-2003 in Geneva, Switzerland), 40 out 
of which (66%), dated 1998-2003, turned out to              
be ceftaroline-resistant [29]. In 2016, in the same 
center, another study was conducted - this time on 
MRSA strains collected in 2013 and 2014. 23 out of 
96 strains (24%) were ceftaroline-resistant [37]. 
 The AWARE report from 2012 informed       
that among 2583 S. aureus strains collected in 
Europe, Russia and Turkey, 2 (0.08%) were cefta-
roline-resistant (MIC, ≥4 mg/l) and 114 (4.4%)  
were ceftaroline-intermediate (MIC, 2 mg/l). Given 
EUCAST (European Committee on Antimicrobial 
Susceptibility Testing) criteria, 116 strains (4.5%) 
were ceftaroline-resistant (MIC, >1 mg/l), 94 (81%) 
out of which came from Russia, Turkey, Italy and 
Hungary [38]. In the USA the first ceftaroline-
resistant MRSA strain was described in 2014 by 
Long et al. and it was isolated from a twenty-year-
old CF patient treated with ceftaroline due to 
recurring respiratory tract infections caused by multi-
drug resistant bacteria (including MRSA) [23]. 
 In 2015 in China, Zhang et al. examined           
251 hospital acquired MRSA strains from ABSSSI 
patients. None of the analyzed strains showed 
resistance to ceftaroline, but 84 of them (33.5%) 
showed intermediate resistance (MIC, 2 mg/l) [39]. 
In the same year, Abbott et al. tested 421 MRSA 
strains collected in Australia (270 from 2017, the 
rest from 2013). 71 (16.9%) out of them were 
nonsusceptible to ceftaroline (MIC, >1.0 mg/l) and 
most of them had MDR phenotype [40]. In Africa, 
37 MRSA strains colonizing patients and 23 
infectious MRSA strains were collected. 10 (16.7%) 
out of them were resistant to ceftaroline [28]. 
 
CONCLUSIONS 
 
 Ceftaroline as a new antibiotic, in most            
cases allows to reach therapeutic effect provided             
in the Summary of Product Characteristics (SPC). 
However, it is very disturbing that in the moment            
of being introduced to market, there have already 
been existing ceftaroline-resistant strains, which 
may indicate that there's a possibility of obtaining 
cross-resistance to ceftaroline while using other             
β-lactam antibiotics in insufficient doses (which can 
be verified by testing archived MRSA strains). 
Laboratory tests prove that resistance to ceftaroline 
may be induced by selecting strains by increasing 
doses of the antibiotic. It shows rather clearly that 
bacteria can survive therapeutic concentration of 
ceftaroline if they have previously been exposed            
to it. Moreover, ceftaroline-resistant strains are 
isolated from patients with clinical symptoms of 
infections.  
 Thus, ceftaroline, just like any other anti-
biotic, may lose its clinical value if it's overused, its 
dosage is incorrect or the rest of β-lactams are 
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overused or dosed incorrectly. Reasonable antibiotic 
therapy is probably the only hope for effective             
use of ceftaroline in the future. However, it is 
impossible to estimate how fast will the resistance-
gaining process progress or what percentage of 
bacteria will it concern. 
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